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Ab stra ct
Qua li ty is a key focus for cli ni cal la bo ra to ries, sin ce it is viewed as a pre requi si te for pa tie nt sa fe ty. It permea tes all three pha ses of the to tal tes ti ng 
pro ce ss (prea na lyti cal, ana lyti cal and pos ta na lyti cal), and re lies hea vi ly on the qua li ty of diag nos tic pro duc ts, su ch as in vit ro (IVD) de vi ces (in stru-
men ts, as says, rea gen ts and spe ci men col lec tion tubes) and me di cal de vi ces (blood col lec tion need les and se ts). The diag nos tic in dus try has im ple-
men ted stri ct cri te ria to as su re that the qua li ty of their pro duc ts throug hout their li fe cycle mee ts the nee ds of their cus to me rs. This is ac com plis hed 
throu gh estab lis hed pro ce sses to de ve lop pro duc ts that meet cus to mer nee ds, as we ll as re gu la to ry requi re men ts nee ded to as su re their sa fe ty and 
e8   ca cy whi le ad he ri ng to good cli ni cal prac ti ces and main tai ni ng hi gh le vel of sa fe ty of hu man sub jec ts that par ti ci pate in cli ni cal tria ls. At the sa me 
ti me, the com mer cial com pa nies fol low good ma nu fac tu ri ng prac ti ces to re du ce va ria bi li ty wit hin their ma nu fac tu ri ng pro ce sses and de li ver pro-
duc ts that are wit hin es tab lis hed spe ci 9  ca tio ns. Howe ver, the hig he st le vel of qua li ty can on ly be ac hie ved when in stru me nt/assay ma nufac tu re rs 
wo rk clo se ly wi th spe ci men con tain me nt ma nu fac tu re rs to as su re to tal system per for man ce.
Key wor ds: prea na lyti cal syste ms; in vit ro diag nos tic de vi ces; la bo ra to ry in stru me nt; rea ge nt; qua lity
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In tro duc tion
Cli ni cal la bo ra to ries rou ti ne ly use com mer cial diag-
nos tic pro duc ts du ri ng the tes ti ng pro ce ss. Diag-
nos tic pro duc ts can be di vi ded in to two ma jor ca-
te go ries: in vit ro diag nos tic (IVD) de vi ces, su ch as 
la bo ra to ry in stru men ts, rea gen ts, as says and blo-
od col lec tion tu bes, and me di cal de vi ces, su ch as 
spe ci men col lec tion de vi ces (need les and se ts). 
Ac cor di ng to the Uni ted Sta tes (US) Co de of Fe de-
ral Re gu la tio ns (CFR), IVD de vi ces are “tho se rea-
gen ts, in stru men ts, and syste ms in ten ded for use 
in diag no sis of di sea se or ot her con di tio ns, in clu di-
ng a de ter mi na tion of the sta te of heal th, in or der 
to cu re, mi ti ga te, treat, or pre ve nt di sea se or its 
seque lae. Su ch pro duc ts are in ten ded for use in 
the col lec tion, pre pa ra tion, and exa mi na tion of 
spe ci mens ta ken from the hu man bo dy” (1). The 
main di* e ren ce between me di cal and IVD de vi ces 
is that IVD de vi ces are used in vit ro for tes ti ng of 
sam ples de ri ved from the hu man bo dy, whi le me-
di cal de vi ces are used in vivo.
The qua li ty of diag nos tic pro duc ts is an es sen tial 
ele me nt of to tal la bo ra to ry tes ti ng qua li ty. La bo ra-
to ry pro fes sio na ls expe ct com mer cial com pa nies 
to ma nu fac tu re hi gh qua li ty pro duc ts. In or der to 
meet the se cus to mer expecta tio ns, diag nos tic com-
pa nies have pro ces ses in pla ce to as su re that they 
suc ces sful ly ma na ge pro du cts throug hout their li-
fe cycle, i.e.:
a) de si gn pro duc ts that meet cus to mer nee ds;
b) ma nu fac tu re them wit hin de ve lo ped spe ci fi ca-
tio ns and ve ry lit tle va ria bi li ty;
c) as su re sa fety and ef fi ca cy of their use;
d) con fo rm wi th re gio nal re gu lato ry requi re men ts 
for their re lea se for cli ni cal use whi le meeting 
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es tab lis hed pro fes sio nal stan dar ds and gui de li-
nes; and
e) mo ni tor the pro du ct per for man ce af ter it is re-
lea sed in to the mar ket pla ce un til its dis con ti-
nua tion from the mar ket (Fi gu re 1).
Ea ch of the se pha ses con tai ns ma ny ste ps, and it is 
pos sib le for er rors to oc cur at any of the nu me rous 
ha nd-o* s, whi ch cou ld be det ri men tal for the qua-
li ty of the product. In or der to avoid this, diag nos-
tic com pa nies ha ve de ve lo ped ro bu st ope ra ti ng 
pro ces ses sup por ted by stan da rd ope ra ti ng pro-
ce du res, which are de sig ned to eli mi na te va ria bi li-
ty, er ro rs and rewo rk.
Pro du ct de si gn
All diag nos tic pro duc ts are de ve lo ped throu gh a 
se ries of pha ses and ga tes whi ch be gin wi th a bu-
si ne ss idea and then de ve lop in to a new pro du ct 
(2). In or der to de si gn a hi gh qua li ty pro du ct, it is 
es sen tial to ad dre ss cus to mer nee ds. This is usual ly 
ac com plis hed throu gh exten si ve cus to mer in te rac-
tio ns, eit her di rec tly (fa ce-to-fa ce in ter views) or in-
di rec tly (sur veys). This “voi ce of cus to mer” is vi tal 
for the de ve lop me nt pro du ct at tri bu tes, so me of 
whi ch are ne ces sa ry to ac hie ve expec ted pro du ct 
qua li ty. On ce this tar ge ted pro du ct pro )  le is de ) -
ned, the pro duct de ve lop me nt pro ce ss can pro-
ceed towar ds de )  ni ng pro du ct spe ci )  ca tio ns (to-
le ran ces), whi ch are al so an es sen tial com po ne nt 
of qua li ty. If the se spe ci )  ca tio ns are too wi de, the 
va ria bi li ty of ma nu fac tu red pro du ct mig ht exceed 
tho se nee ded to as su re expec ted qua li ty. On the 
ot her ha nd, spe ci )  ca tio ns that are too nar row may 
present a prob lem for the ma nu fac tu ra bi li ty of the 
pro du ct, sin ce this mig ht be beyo nd the ca pa bi li ty 
of the ma nu fac tu ri ng pro ce ss. Du ri ng this pe riod, it 
is cri ti cal to te st the se spe ci )  ca tio ns in the con text 
of pro du ct per for man ce and as su re that at their 
extre mes the per for man ce of the pro du ct is sti ll ac-
cep tab le (i.e. that the qua li ty of the pro du ct is uni-
fo rm). This is usual ly an ite ra ti ve pro ce ss, whi ch is 
com ple ted usi ng pro to types or re sear ch rea gen ts.
As pa rt of this pro ce ss, it is al so im por ta nt to se le ct 
the pro per ma te rials that wi ll be used to ma nu fac-
tu re the pro du ct, sin ce pro du ct qua li ty is di rec tly 
de pen de nt on the qua li ty of the raw ma te ria ls 
used for its pro duc tion. On ce the spe ci )  ca tio ns 
are de )  ned, the pro du ct design is de ve lo ped and 
manufac tu ra bi li ty is as ses sed.
Pro du ct ma nu fac tu ri ng
As men tio ned pre vious ly, ma nu fac tu ri ng qua li ty 
of the diag nos tic pro duc ts is de pen de nt on the 
con sis ten cy and re pea ta bi li ty of the ma nu fac tu ri-
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FI GU RE 1. Pro duct life cycle.
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ng pro ces ses. In or der to main tain this con sis ten cy, 
the re are se ve ral key areas of focus, su ch as:
• Ma nufac tu ra bi li ty of the Desi gn
• Ma nu fac tu ri ng Equip me nt De si gn
• Ma nu fac tu ri ng Pro ce ss De ve lop me nt and Va li-
da tion
• In spec tion Con trol Pla ns
• Chan ge Con trol
The ma nu fac tu ra bi li ty of the de si gn is an im por ta-
nt ele me nt that will sub sequen tly de ter mi ne the 
com plexi ty, ca pa bi li ty (Cpk) and con sis ten cy of the 
ma nu fac tu ri ng equip me nt. Ma ny com pa nies em-
ploy De si gn for Ma nu fac tu ra bi li ty and As sem bly 
(DFMA) tec hniques to en su re the Voi ce of Ma nu fac-
tu ri ng is hea rd ear ly in the de si gn pha se. DFMA is a 
syste ma tic met ho do lo gy used to as se ss if the de si-
gn can be ma nu fac tu red and as sem bled at the tar-
ge ted co st, qua li ty and ope ra tio nal equip me nt ef-
fec ti ve ne ss tar ge ts. A ma nu fac tu ri ng frien dly de si-
gn wi ll re du ce the num ber of pro du ct de si gn chan-
ges and ma nu fac tu ri ng de si gn chan ges that may 
be requi red po st pro du ct re lea se. Ne ces sa ry de si-
gn chan ges iden ti ) ed ear ly in de ve lop me nt are sig-
ni )  can tly le ss cos tly and ti me con su mi ng than tho-
se iden ti ) ed in the la ter sta ges of the pro ce ss. The 
com plexi ty of the de si gn (i.e. pro du ct to le ran ces, 
num ber of com po nen ts, sur fa ce treat men ts) has a 
di re ct cor re la tion on the qua li ty of the pro du ct.
The ma nu fac tu ri ng equip me nt de si gn al so has a di-
re ct im pa ct on pro du ct qua li ty. Equip me nt de sig ns 
that ac cou nt for the fu ll va ria bi li ty in com po nen ts 
for in the han dli ng and as sem bly pro ce ss re su lt in re-
du ced )  nal pro du ct va ria bi li ty. Ro bu st as sem bly tes-
ti ng usi ng com po nen ts at the mi ni mum and maxi-
mum of their to le ran ce wi ll en su re the com po ne nt 
va ria bi li ty is fa ctored in to the equip me nt de si gn.
Duri ng ma nu fac tu ri ng pro ce ss de ve lop me nt and 
va li da tion ac ti vi ties, the ma nu fac tu ri ng pro ce ss ste-
ps that im pa ct the cri ti cal to qua li ty (CTQs) cha rac-
te ris ti cs of the pro du ct are de )  ned throu gh De sig-
ned Expe ri men ts (DOEs). DOEs are used to de )  ne 
the ran ges of the Key Pro ce ss In put Va riab les (KPI-
Vs) and their im pa ct on the CTQs. KPI Vs are ma nu-
fac tu ri ng pro ce ss va riab les (pres su re, tem pe ra tu re 
etc.) that ha ve the grea te st e* e ct on out put va riab-
les (im pa ct stren gth, peel fo rce) of the pro du ct bei-
ng ma nu fac tu red. The pro ce ss va li da tion wi ll chal-
len ge the se ran ges in the ope ra tion qua li )  ca tion 
(OQ) pha se to en su re the en ti re ope ra ti ng ran ge as 
we ll as the in te rac tio ns be tween proces si ng pa ra-
me te rs. On ce ve ri ) ed throu gh the OQ pha se, the 
per for man ce qua li )  ca tion (PQ) pha se wi ll chal len ge 
the sho rt te rm ca pa bi li ty (Cpk) of the pro ce ss as 
we ll as the pro jec ted lo ng te rm ca pa bi li ty (Ppk) 
throu gh mul tip le pro ce ss ru ns by trai ned ope ra to rs.
Throu gh ri sk ma na ge me nt tec hniques, su ch as Pro-
ce ss Fai lu re Mo des E* ec ts Ana lysis (pFMEA), po ten-
tial pro ce ss ris ks are iden ti ) ed and mi ti ga ted. pFMEA 
is a syste ma tic met hod of eva lua ti ng a ma nu fac tu ri-
ng pro ce ss in or der to iden ti fy po ten tial fai lu re mo-
des in he re nt to the pro ce ss, as ses si ng the po ten tial 
im pa ct of tho se fai lu re mo des, and de ter mi ni ng 
met ho ds to eli mi na te/prevent or mi ti ga te their oc-
cur ren ce. Miti ga tion can be ac com plis hed throu gh 
equip me nt de si gn alo ng wi th the in spec tion con-
trol plan. A pro perly powe red in spec tion plan en su-
res that iden ti ) ed pro du ct CTQs are chal len ged at a 
set frequen cy. The in spec tion pro ce ss mu st be qua-
li ) ed throu gh an ap prop ria te Mea su re me nt System 
Ana lysis (MSA) that chal len ges the ope ra tor in g uen-
ce, mea su ri ng tec hnique as we ll as the va ria bi li ty in 
the par ts that are mea su red. MSA is a spe cial ly de-
sig ned expe ri me nt that see ks to iden ti fy the com-
po nen ts of va ria tion in the mea su re ment.
Fi nal ly, a ro bu st chan ge con trol pro ce ss for pro per ly 
qua li ) ed pro du ct and pro ce ss chan ges shou ld be 
im ple men ted. Chan ges to produ ct de si gn / ma te-
ria ls mu st al so be re va li da ted so pro du ct per for-
man ce is not ad ver se ly a* ec ted. Ad di tio nal ly, chan-
ges to the ma nu fac tu ri ng pro ce ss need to be re va li-
da ted to en su re that va li da ted pro ces si ng pa ra me-
te rs are una* ec ted as we ll as their im pa ct on CTQs.
Es ta blis hme nt of sa fe ty and 
e)   ca cy of use
On ce the ma nu factu ra bi li ty of a pro du ct has been 
ac hie ved, se ve ral lo ts of pro du ct are ma de usi ng 
the es tab lis hed ma nu fac tu ri ng pro ce ss. This as se-
sses the per for man ce of the pro du ct in real use and 
is ac hie ved by eva lua ti ng sa fe ty and ed   ca cy (i.e. 
de ter mi ne that the pro du ct wi ll not cau se ha rm to 
Biochemia Medica 2010;20(2):207–14
210
hu ma ns and wi ll per fo rm as in ten ded). At the on set 
of this ac ti vi ty, it is ne ces sa ry to de ve lop a cli ni cal 
tes ti ng plan whi ch wi ll de )  ne the sco pe of tes ti ng 
(ana lytes, in stru men ts, spe ci men col lec tion tu bes) 
and is exe cu ted throu gh in ves ti ga tio ns wi th hu-
man sub jec ts or ma te ria ls de ri ved from hu man 
sub jec ts (i.e. cli ni cal tria ls). The qua li ty of the da ta 
ob tai ned from the se cli ni cal tria ls is an impor ta nt 
compo ne nt of the qua li ty of a diag nos tic pro du ct. 
If the cli ni cal tria ls are not con duc ted in a con trol-
led and re gu la ted man ner usi ng good cli ni cal prac-
ti ces, the in for ma tion on pro du ct per for man ce wi ll 
not reg e ct its true per for man ce in a cli ni cal en vi-
ron me nt. Fir st, the trial sam ple si ze, su ch as the 
num ber of sub jec ts or spe ci me ns that are tes ted in 
the se tria ls, mu st be sud   cie nt (i.e. ha ve the ap prop-
ria te sta tis ti cal power) to al low ge ne ra tion of con-
clu sio ns wi th a hi gh deg ree of cer tain ty. Seco nd, 
the trial has to be de sig ned to gene ra te mea nin gful 
da ta, and this de si gn has to be exe cu ted tin su ch a 
man ner to as su re da ta in teg ri ty. This in vol ves stu dy 
mo ni to ri ng and approp ria te da ta ma na ge me nt. 
Lastly, the da ta mu st be ana lyzed uti li zi ng the sta-
tis ti cal met ho do lo gy to ge ne ra te ap propria te re sul-
ts. Du ri ng this en ti re pro ce ss, it is al so im pe ra ti ve to 
gua ran tee the sa fe ty of the sub jec ts that are par ti-
ci pa ti ng in the cli ni cal tria ls. In sti tu tio nal Re view 
Boar ds or Et hi cs Com mit tees re view ea ch study de-
si gn prior to im ple men ta tion to as su re that sub jec-
ts wi ll not be expo sed to un due ri sk by their par ti ci-
pa tion in the stu dy. Sub jec ts are al so ma de awa re 
of stu dy ris ks prior to par ti ci pa tion, sin ce ris ks are 
dis clo sed in the in for med con se nt that is sig ned by 
the par ti ci pan ts be fo re the sta rt of the trial.
Regu la to ry requi re men ts
Be fo re cli ni cal use, diag nos tic pro duc ts mu st re cei-
ve appro val for use from the re le va nt re gu la to ry bo-
dy. The ap pro val pro ce ss is hig hly de pen de nt on 
the type of de vi ce in ques tion. Me di cal and IVD de-
vi ces are usual ly di vi ded in to di* e re nt clas ses, ba-
sed on the ri sk in use. It is ne ces sa ry to ap ply the 
cor re ct re gu la tio ns for ea ch de vi ce cla ss, whi ch va ry 
geog rap hi cal ly (Tab le 1). Typi cal ly, Cla ss III me di cal 
de vi ces rep resent the hig he st risk, and Cla ss I the 
lowe st. Depen di ng on the de vi ce ri sk the re are dif-
fe re nt re gu la to ry requi re men ts that the de vi ce ma-
nu fac tu re rs need to com ply wi th in or der to ob tain 
ap pro val for their dis tri bu tion to the mar ket (see 
Tab le 1). As an exam ple, blood col lec tion de vi ces 
(need les and blood col lec tion se ts), whi ch are me di-
cal de vi ces mo st com mon ly used in la bo ra to ry tes-
ti ng, are clas si ) ed as Cla ss II (Uni ted Sta tes) and Cla-
ss IIa (Euro pean Union). In the US, in or der to se ll a 
new blood collec tion tu be, the ma nu fac tu rer nee ds 
to con du ct cli ni cal tria ls and mec ha ni cal tes ti ng to 
as su re that the de vi ce is sa fe for use. The se da ta are 
sub mit ted to the Food and Drug Ad mi nis tra tion 
(FDA) for ap pro val prior to laun ch. Ac cor di ng to the 
EU Di rec ti ve, it is enou gh that the ma nu fac tu rer has 
the pro du ct per for man ce and as sem bly da ta on )  le 
and cer ti )  ca tion that con ) r ms the de vi ce ste ri li ty.
The re gu la to ry lan dsca pe for me di cal and IVD 
devi ces is hig hly va riab le and con stan tly chan gi ng. 
In so me re gions, re gu la to ry requi re ments are evol-
vi ng and tran spa re nt, and in ot he rs, sta tic and un-
clear. Mo st ma jor mar ke ts are stric tly re gu la ted wi-
th an em pha sis on pre-mar ket con trol.
In to day’s ra pid bu si ne ss en vi ron me nt, it is im por-
ta nt to uti li ze stan dar ds for as su ri ng pro du ct com-
plian ce and to fa ci li ta te ac cep ta nce of me di cal de-
vi ces wor ldwi de.
This is al so in crea si ng the de ma nd for bet ter re gu-
la to ry gui dan ce to en su re that pro duc ts are sa fe 
and e* ec ti ve be fo re en te ri ng the mar ket.
FDA re lies on the cur re nt Good Ma nu fac tu ri ng 
Prac ti ce (GMP) requi re men ts of 21 CFR pa rt 820 
Qua li ty System Re gu la tion (QSR). Out si de the me-
di cal in dus try, the in ter na tio nal stan dar ds of the 
Qua li ty Ma na ge me nt System (QMS) are ba sed on 
ISO 9001, and for the Me di cal De vi ce in dus try, ISO 
13485. ISO 13485 “Me di cal De vi ces, Requi re men ts 
for Re gu la to ry Pur po se s” is the stan da rd re cog ni-
zed by ma ny coun tries as the way to ob tain GMP.
The ISO 13485 stan da rd is uti li zed as the QMS stan-
da rd that is ap pli cab le to ma ny re gio ns arou nd the 
world for re gu la to ry com plian ce. The im ple men ta-
tion of a QMS is requi red for mar ke ti ng of me di cal 
de vi ces in di* e re nt re gio ns. Whi le the Uni ted Sta-
tes re lies on FDA in ves ti ga to rs to as su re com plian-
ce to the QSR, ot her re gio ns mu st re ly on ISO 
13485 cer ti )  cation for re gu la to ry com plian ce.
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Uni ted Sta tes* Eu ro pean Unio n**
• Cla ss I (Ge ne ral Con tro ls)
• Cla ss II (Spe cial Con tro ls)
• Cla ss III (Pre-mar ket 
Ap pro val)
• Cla ss I (Tec hni cal Fi le on ly)
• Cla ss I ste ri le (ad di tio nal 
Cer ti )  ca tion)
• Cla ss I mea su ri ng (ad di tio nal 
Cer ti )  ca tion)
• Cla ss IIa (ad di tio nal 
Con for mi ty As ses sme nt)
• Cla ss IIb (ad di tio nal 
Con for mi ty As ses sme nt)
• Cla ss III (ad di tio nal 
Con for mi ty As ses sme nt)
* Ac cor di ng to US Co de of Fe de ral Re gula tio ns, Cla ss I de vi ces 
pre se nt mi ni mal po ten tial for ha rm to the user and are of ten sim-
pler in de si gn than Cla ss II or Cla ss III de vi ces. The se de vi ces are 
sub je ct on ly to ge ne ral con tro ls. Ge ne ral con tro ls co ver su ch is-
sues as ma nu fac tu rer re gis tra tion wi th the FDA, good ma nu fac tu-
ri ng tec hniques, pro per bran di ng and la be li ng, no ti )  ca tion of the 
FDA be fo re mar ke ti ng the de vi ce, and ge ne ral re por ti ng pro ce-
du res. The se con tro ls are dee med sud   cie nt to pro vi de rea so nab-
le as su ran ce of the sa fe ty and e* ec tive ne ss of the de vi ce.
Cla ss II de vi ces are tho se for whi ch ge ne ral con tro ls alo ne are in-
sud   cie nt to as su re sa fe ty and e* ec ti ve ne ss, and ad di tio nal exis-
ti ng met ho ds are avai lab le to pro vi de su ch as su ran ces. The re fo-
re, Cla ss II de vi ces are al so sub je ct to spe cial con tro ls in ad di tion to 
the ge ne ral con tro ls of Cla ss I de vi ces. Spe cial con tro ls may in clu de 
spe cial la be li ng requi re men ts, man da to ry per for man ce stan dards, 
and pos tmar ket sur veil lan ce. De vi ces in Cla ss II are he ld to a hig-
her le vel of as su ra nce than Cla ss I de vi ces that they wi ll per fo rm 
as in di ca ted and wi ll not cau se inju ry or ha rm to pa tie nt or user.
Cla ss III de vi ces are tho se for whi ch in sud   cie nt in for ma tion exis ts 
to as su re sa fe ty and e* ec ti ve ne ss so le ly throu gh the ge ne ral or 
spe cial con tro ls sud   cie nt for Cla ss I or Cla ss II de vi ces. Su ch a de-
vi ce nee ds pre mar ket ap pro val, a scien ti ) c re view to en su re the 
de vi ce’s sa fe ty and e* ec ti ve ne ss, in ad di tion to the ge ne ral con-
tro ls of Cla ss I.
** Ac cor di ng to the EU Di rec ti ve, for Cla ss I medi cal de vi ces, whi-
ch pre se nt lowe st ri sk for ha rm to the user, the manu fac tu rer has 
to pro du ce a technical ) le, whi ch in clu des sa fe ty and ed   ca cy as-
ses sme nt as we ll as ad he ren ce to rele va nt stan dar ds. In ad di tion, 
ma nu fac tu re rs of Cla ss I ste ri le pro duc ts, as we ll as de vi ces wi th a 
mea su ri ng fun ction mu st ap ply to a No ti ) ed Bo dy for cer ti )  ca tion 
of the as pec ts of ma nu fac tu re re la ti ng to ste ri li ty or met ro lo gy.
Be si des com ple tion of a tec hni cal )  les and ob tai ni ng nee ded cer-
ti )  ca tes, for Cla ss II and III de vi ces it is al so requi red to con du ct 
a con for mi ty as ses sme nt by a No ti ) ed Bo dy. The con for mi ty as-
ses sme nt in vol ves mo re exten si ve do cu me nt and fa ci li ty re views.
TAB LE 1. Clas si )  ca tion of medi cal devi ces.Ot her more im por ta nt stan dar ds for me di cal de vi-
ces pro vi de gui dan ce for ri sk ma na ge me nt (ISO 
14971), pro du ct ste ri li ty (ISO 11607, ISO 11135 and 
ISO 11137), ma te rial bio com pa ti bi li ty (ISO 10993) 
and cli ni cal tria ls (ISO 14155). Al thou gh ISO stan-
dards are ve ry com mon ly used wor ldwide, the re 
are ot her stan dar ds that are used by re gu la to ry 
age ncies to as se ss per for man ce of diag nos tic pro-
duc ts. Exam ples are gui de li nes pro du ces by the 
Cli ni cal Stan dar ds La bo ra to ry In sti tu te (CLSI) su ch 
as EP07-A2 (3), EP09-A2 (4), EP17-A (5), EP25-A (6), 
GP34-P (7). For in stan ce, EP07-A2 out li nes pro ce-
du res for ma nu fac tu re rs to screen po ten tial ly in-
ter fe ri ng sub stan ces, quan ti fy in ter fe ren ce e* ec ts, 
and con )  rm in ter fe ren ce in pa tie nt sam ples. On 
the ot her ha nd, EP17-A pro vi des gui dan ce for de-
ter mi ni ng the lower li mit of de tec tion of cli ni cal la-
bo ra to ry met ho ds, for ve ri fyi ng clai med li mi ts, 
and for the pro per use and in ter pre ta tion of the se 
li mi ts. Ma ny coun tries out si de of Eu ro pe and the 
Uni ted Sta tes de pe nd on re gu la to ry stan dar ds to 
as su re their or ga ni za tion’s com pliance, as they do 
not ha ve adequa te re sour ces to con duct in spec-
tio ns out si de their bor de rs.
The ISO 13485 cer ti )  ca tion as su res that me di cal 
de vi ce com pa nies com ply wi th a known regu la to-
ry stan da rd. The QMS of the me di cal de vi ce com-
pa ny is al so cer ti ) ed by a re gis trar who rou ti ne ly 
au di ts the or ga ni za tion to ve ri fy that com plian ce is 
main tai ned.
Main tai ni ng the ISO cer ti )  ca tion is on ly a pa rt of 
the pro ce ss. Re gio nal ly, the re are va rious requi re-
men ts and ad di tio nal pro ces ses mu st be in pla ce. 
So me of the se in clu de re gu la to ry sub mis sion ac ti-
vi ties, ad ver se eve nt re por ti ng and com mu ni ca tio-
ns wi th re gu la to ry agen cies.
A va rie ty of In ter na tio nal Stan dar ds are uti li zed by 
ma ny com panies to ad dre ss bu si ne ss, qua li ty, cli-
ni cal and re gulato ry nee ds, and play a sig ni )  ca nt 
ro le in rai si ng the le ve ls of sa fe ty, re lia bi li ty and ef-
)  cien cy. In ter na tio nal stan dar ds are al so use ful to 
in dus trial and bu si ne ss or ga ni za tio ns, go ver nmen-
ts and re gulato ry bo dies and ul ti ma te ly, the end 
user. The se stan dar ds pro vi de an im pli cit pat hway 
of en su ri ng a le vel of pro du ct qua li ty.
Po st mar ket sur veil lan ce
On ce the pro du ct is laun ched, it is im por ta nt to 
mo ni tor its per for man ce over ti me in or der to en-
sure con sta nt pro du ct qua li ty. This is known as 
po st mar ket sur veil lan ce. It can be ac ti ve, su ch as 
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con duc ti ng oc ca sio nal stu dies to as se ss per for-
man ce or by so li ci ta ti ng cus to mer feed ba ck or 
pas si ve by mo ni to ri ng cus to mer com plain ts (Fi gu-
re 2). Re gar dle ss of the way that the feed ba ck on 
pro du ct per for man ce is ob tai ned, if the in di ca tion 
of pro du ct mal fun ction is con ) r med, IVD com pa-
nies im me dia te ly as se ss the deg ree of ri sk that this 
mal fun ction can po se on the sa fe ty and ed   ca cy of 
the de vi ce as we ll as its root cau se. If this ri sk is 
dee med unac cep tab le, the pro du ct is wit hdrawn 
from the mar ket and ste ps are ta ken to as su re that 
this does not hap pen again. Pro du ct mal fun ction 
is usual ly due to a ma nu fac tu ri ng er ror, in whi ch 
ca se pro ces ses are put in pla ce to pre ve nt this er-
ror. Howe ver, it can so me ti mes re su lt from an in-
he re nt g aw of the de vi ce. In that ca se, re de si gn 
mig ht be the on ly so lu tion.
So far, we ha ve des cri bed pro ces ses that IVD com-
pa nies use to as su re qua li ty of their o* e rin gs. 
However, of ten this is not sud   cie nt to ac hie ve to-
tal qua li ty in la bo ra to ry diag nos ti cs. Owi ng to tec-
hno lo gy ad van ce men ts, ana lyti cal in stru men ts for 
the cli ni cal la bo ra to ry are be co mi ng in crea sin gly 
sop his ti ca ted and new and mo re sen si ti ve as says 
and rea ge nt tests are de ve lo ped ever fas ter. The re-
fo re, qua li ty syste ms for mo ni to ri ng la bo ra to ry te-
st ac cu ra cy and ed   cien cy need to fo cus beyo nd 
ju st the per for man ce of in di vi dual ana lyti cal de vi-
ces to en com pa ss the en ti re la bo ra to ry tes ti ng 
pro ce ss. La bo ra to ry pro fes sio nals shou ld ob tain 
ac cu ra te re sul ts from “the syste m”, in clu di ng sam-
ple col lec tion tu bes, in stru men ts and rea gen ts. 
The highe st le vel of qua li ty is ac hie ved on ly when 
in stru me nt/assay ma nu fac tu re rs and sam ple col-
lec tion ma nu fac tu re rs coo pe ra te to de li ver to tal 
system per for man ce. Be cau se of this, the re is a ri si-
ng need for the ma nu fac tu re rs of the instru men ts, 
rea gen ts/assays and the sam ple col lec tion de vi-
ces (su ch as eva cua ted tu bes and shar ps) to wo rk 
to get her to de li ver to tal system per for man ce (Fi-
gu re 3).
Devi ce ma nu fac tu re rs, tu be ven do rs, and cli ni cal 
la bo ra to ry pro fes sio na ls ali ke need to un der sta-
nd the in te rac tio ns be tween tu bes, rea gen ts and 
in stru men ts and the con tri bu tion of ea ch to to tal 
system per for man ce and sub sequen tly, ac cu ra te 
re sul ts. Ana lytical de vi ce ma nu fac tu re rs and spe-
ci men con tain me nt ven do rs mu st wo rk as par-
tne rs du ri ng in stal la tion of new la bo ra to ry syste-
ms and va li da te the en ti re la bo ra to ry tes ti ng pro-
ce ss from sam ple col lec tion to re por ti ng of re-
sults.
It may not be always prac ti cal or even pos sib le for 
tu be ma nu fac tu re rs to te st their pro duc ts on all 
as say plat for ms. The re fo re, con sis ten cy of tu be ad-
di ti ves and the e* e ct of all tu be com po nen ts on 
as say per for man ce and te st re sul ts throug hout the 
dyna mic ran ge of the as says shou ld be ve ri ) ed on 
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FI GU RE 2. Pro du ct inci de nt repo rt (PIR) rates. Wor ldwi de com plai nt ra tes for all pro duc ts for BD Diag nos ti cs – Prea na lyti cal Syste ms. 
Pre sen ted are mon thly com plai nt ra tes and the li near com plai nt ra te in PI Rs / mil lion uni ts so ld.
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ray of ana lytes for tes ti ng shou ld be se lec ted usi ng 
se ve ral cri te ria:
a) me di cal sig ni fi can ce;
b) frequen cy of use;
c) as say met ho do logy;
d) che mi cal struc tu re, etc.
in or der to iden ti fy po ten tial in terfe ren ces. Si mi lar 
stra te gy shou ld be ap plied to the se lec tion of in-
strument plat for ms for tes ti ng. Likewi se, when a 
new as say or in stru me nt plat fo rm is un der de ve-
lop me nt, the ma nu fac tu rer shou ld eva lua te the 
per for man ce wi th spe ci me ns col lec ted in tu bes 
from the ma jor glo bal sup plie rs of sam ple col lec-
tion devi ces and as se ss in com pa ti bi li ties that oc cur 
in si de and out si de the tu be. Ad di ti ve com po nen ts 
pre se nt in si de the tu be can a* e ct as say per for-
man ce. On the ot her ha nd, the mec ha ni cal com po-
nen ts of the spe ci men con tai ner, su ch as dia me ter, 
heig ht, wa ll ma te rial, stop per con )  gu ra tion and 
ma te rial ha ve to be com pa tib le wi th the mec ha ni-
cal com po nen ts of the in stru me nt ana lyze rs. Ad di-
tio nal ly, the ma nu fac tu re rs of spe ci men con tain-
me nt de vi ces shou ld eva luate new tu bes un der 
stres sed con di tio ns – par tial ly ) l led tu bes, extre me 
tem pe ra tu res and ship pi ng con di tio ns, and pro-
lon ged con ta ct ti me of the sam ple wi th the tu be 
ad di ti ves – to si mu la te “real li fe” con di tions.
Be fo re laun chi ng a new spe ci men col lec tion de vi-
ce to the mar ket, spe ci men con tain me nt ma nufac-
tu re rs shou ld wo rk to get her wi th in stru me nt and/
or as say ma nu fac tu re rs to ac hie ve to tal system 
per for man ce, op ti mum ef fi cien cy and TAT. IVD 
com pa nies that are con cer ned about to tal qua li ty 
in la bo ra to ry diagnos ti cs ha ve de di ca ted re sour-
ces to as su re to tal system per for man ce. The se in-
di vi dua ls col la bo ra te with col lea gues from in stru-
me nt/assay/tube com pa nies to ad dre ss par ti cu lar 
custo mer com plain ts and )  nd root cau se and ways 
to mi ti ga te it. They are al so invol ved in sha ri ng in-
for ma tion about new pro du ct ge ne ra tion ma ps 
and wor ki ng wi th their res pec ti ve Re sear ch and 
De ve lop me nt grou ps to as su re mu tual com pa ti bi-
li ty of pro duc ts. In ad di tion, total system per for-
man ce shou ld be demon stra ted ba sed on joi nt cli-
nical stu dies and sha red wi th cus to me rs. When is-
sues ari se, su ch as as say in ter fe ren ces, it is cru cial 
that all ven do rs who con sti tu te a par ti cu lar la bo ra-
to ry system wo rk wi th their joi nt cus to mers to re-
sol ve the is sue. To tal qua li ty in la bo ra to ry diag nos-
ti cs can on ly be ac hie ved throu gh mo ni to ri ng of 
to tal system per for man ce.
As des cri bed, IVD com pa nies ha ve in sti tu ted dis-
tin cti ve pro ces ses that are de sig ned to as su re 
maxi mum qua li ty of their o* e rin gs. Ma ny of the se 
pro ces ses are over lap pi ng and con tain multip le 
chec ks and ba lan ces that we re de sig ned to pre ve-
nt ero sion of sa fe ty and pro du ct qua li ty. This bui lt-
in re dun dan cy is de li be ra te, as it is a way to as su re 
stea dy main te nan ce of pro du ct qua li ty throu gh 
mul tip le ha nd-o* s du ri ng the pro du ct li fe cycle. 
On the ot her ha nd, re gu la to rs play an im por ta nt 
ro le in main tai ni ng nee ded IVD pro du ct qua li ty by 
set ti ng per for man ce stan dar ds en for ced throu gh 
for mal pro du ct ap pro val pro ces ses be fo re al lowi-
ng their dis tri bu tion in the mar ketpla ce. As dis cus-
sed pre viou sly, ad di tio nal focus is now cen te red 
on to tal system per for man ce whi ch in clu des the 
in te rac tion of the la bo ra to ry in stru me nt, the as say 
and the spe ci men con tain me nt de vi ce.
Ac knowled ge men ts
The aut ho rs wou ld li ke to tha nk Ju lie Ra vo for her 
wo rk on edi ting this ma nus cri pt.
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Kva li te ta u la bo ra to rij skoj di jag nos ti ci: ulo ga ko mer ci jal nih tvr tki
Sažetak
Kva li te ta je ključna točka u ra du kli ničkih la bo ra to ri ja, bu dući da se smat ra pre duv je tom za omo gućava nje si gur no sti bo les ni ka. Pro teže se kroz 
sve tri fa ze cje lo kup nog la bo ra to rij skog is pi ti va nja (pri jea na li tičku, ana li tičku i pos li jea na li tičku fazu) te u ve li koj mje ri ovi si o kva li te ti di jag nos-
tičkih proiz vo da, kao što su IVD (en gl. in vit ro de vi ces) (uređaji, tes to vi, rea gen si i ep ru ve te) te me di cin ski proiz vo di (ig le i pri bor za uzi ma nje kr vi). 
Di jag nos tička in dus tri ja pra ti stro ga pra vi la ka ko bi se omo gućilo da kva li te ta nji ho vih proiz vo da ti je kom ci je log vi je ka tra ja nja proiz vo da od go-
va ra pot re ba ma ko ris ni ka. To se pos tiže us pos tav lje nim pro ce si ma za raz voj proiz vo da ko ji od go va ra ju pot re ba ma ko ris ni ka. Ta kođer i za kon ski 
zah tje vi tre ba ju osi gu ra ti nji ho vu si gur no st i učin ko vi to st pro pi su jući dob ru kli ničku prak su i od ržava nje vi so kog stup nja si gur nos ti oso ba koji 
sud je lu ju u kli ničkim po ku si ma. Is to dob no, ko mer ci jal ne tvr tke sli je de dob re proiz vođačke prak se, ka ko bi sma nji le va ri ja bil no st unu tar svo jih 
proiz vođačkih pro ce sa i is po ručile proiz vo de ko ji od go va ra ju do go vo re nim spe ci 9  ka ci ja ma. Međutim, naj viši se stu panj kva li te te može pos tići 
je di no u us koj su rad nji proiz vođača in stru me na ta/testova s proiz vođačima ep ru ve ta, ka ko bi se osi gu rao za do vo lja va jući učinak cje lo kup nog sus-
ta va.
Ključne ri ječi: pri jea na li tički sus ta vi; IVD proiz vo di; la bo ra to rij ski uređaj; rea ge ns; kva li te ta
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